Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Nykode Therapeutics Enters into Collaboration Agreement with Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases

11/23/2021 | 12:45am EST

Nykode Therapeutics announced that it has entered into a license and collaboration agreement with Regeneron for the discovery, development and commercialization of potential new vaccines for cancer and infectious diseases. The agreement includes five distinct programs, three within cancer and two within infectious diseases. Each of these may include several vaccine candidates, all of which being eligible for milestone and royalty payments. The vaccines will combine Regeneron?s unique antigen selection expertise and innovative VelociSuite in vivo models with Nykode Therapeutics? modular vaccine platform and expertise in vaccine design. Nykode Therapeutics will be responsible for vaccine generation and characterization, as well as product supply through the end of Phase 1 trials. Regeneron willbe responsible for antigen identification, preclinical and clinical development, manufacturing and commercialization. Additionally, Nykode Therapeutics will potentially be eligible to receive more than USD 875 million in milestone payments, plus high single-digit to low double-digit tiered royalties on sales of commercialized products arisingfrom the collaboration, bringing the total potential value of the agreement to more than USD 925 million, plus royalties. Regeneron will cover costs for research, as well as potential clinical, regulatory, manufacturing and commercialization activities.


ę S&P Capital IQ 2021
All news about REGENERON PHARMACEUTICALS
01/13WHO recommends Eli Lilly, GSK-Vir's drugs, widening COVID-19 treatment pool
RE
01/13Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results a..
PR
01/12EUROPEAN MIDDAY BRIEFING - Stocks Higher as -3-
DJ
01/12EUROPEAN MIDDAY BRIEFING - Stocks Higher as -2-
DJ
01/11ADRs Close Higher; Nokia Trades Actively
DJ
01/10Regeneron and ultragenyx collaborate to commercialize evkeeza (evinacumab) outside the ..
AQ
01/10Regeneron's Covid-19 Antibody Cocktail Had 2021 U.S. Sales Near $6 Billion
DJ
01/10REGENERON PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulatio..
AQ
01/07Regeneron Pharmaceuticals, Ultragenyx Pharmaceutical Strike Commercialization Deal for ..
MT
01/07Regeneron, Ultragenyx Ink International Deal on Cholesterol Drug Evkeeza
DJ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 15 515 M - -
Net income 2021 7 967 M - -
Net cash 2021 4 180 M - -
P/E ratio 2021 8,74x
Yield 2021 -
Capitalization 64 327 M 64 327 M -
EV / Sales 2021 3,88x
EV / Sales 2022 4,28x
Nbr of Employees 9 766
Free-Float -
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 615,24 $
Average target price 697,73 $
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS-2.58%64 327
GILEAD SCIENCES, INC.-1.16%90 027
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.73%52 665
BIONTECH SE-23.97%47 338
BEIGENE, LTD.-11.92%24 519